

# First Quarter 2015

---

**Management's Discussion and Analysis**  
For the Three Months Ended February 28, 2015

**Convalo Health International Corp.**

*The following Management's Discussion and Analysis ("MD&A") of the financial condition and results of operations of Convalo Health International Corp. ("Convalo" or the "Company"), prepared as of April 27<sup>th</sup>, 2015, should be read in conjunction with the consolidated financial statements for the first quarter ended February 28, 2015, including the notes therein. The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"). Unless otherwise specified, all financial data is presented in Canadian dollars.*

*Additional information relevant to the Company is available for review on SEDAR at [www.sedar.com](http://www.sedar.com).*

**Table of Contents**

Page 2	Caution Regarding Forward-Looking Statements
Page 3	Selected Annual Information
Page 4	About Our Business and Operating Results
Page 7	Financial Condition
Page 10	Accounting and Disclosure Matters
Page 11	Financial Instruments and Risk Management
Page 12	Risk Factors

**CAUTION REGARDING FORWARD-LOOKING STATEMENTS**

Information included or incorporated by reference in this report may contain forward-looking statements. This information may involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "plan," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Readers are cautioned regarding statements discussing profitability; growth strategies; anticipated trends in our industry; our future financing plans; and our anticipated needs for working capital. Actual events or results may differ materially from those discussed in forward-looking statements. There can be no assurance that the forward-looking statements contained in this report will in fact occur. The Company bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS MD&A PRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS MD&A AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, THE COMPANY DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED BY APPLICABLE SECURITIES LEGISLATION.

**1<sup>st</sup> QUARTER HIGHLIGHTS**

- Started operations in May of 2014 and launched first full stand-alone addiction rehabilitation center in November of 2014.
- Listed on the TSX Venture Exchange through Amalgamation with Valiant, a CPC, effective February 11, 2015.
- Increased cash on the Balance Sheet to \$5,402,596 from \$1,840,298.
- Generated revenues for the quarter ended February 28, 2015 of \$1,201,225.
- Gross profits of \$796,027 for the quarter ended February 28, 2015.
- Gross margin of 63.3% for the quarter ended February 28, 2015.

**SELECTED FIRST QUARTER INFORMATION**

	<b>Three Months Ended February 28, 2015</b>	<b>Three Months Ended February 28, 2014</b>
Revenue	\$1,201,225	\$ -
Gross Margin	66.3%	-
Adjusted EBITDA before new facility start-up costs	\$245,677	(\$28,255)
Adjusted EBITDA <sup>(1)</sup>	\$177,359	(\$28,255)
	<b>February 28, 2015</b>	<b>November 30, 2014</b>
Cash	\$5,402,596	\$1,840,298
Working Capital	\$5,602,073	\$1,593,345

<sup>(1)</sup> Throughout this document, "Adjusted EBITDA" and "Adjusted EBITDA before business development costs" are used as profitability measures. Please refer to the "Non-IFRS Measures" section of this MD&A for further discussion on these measures.

<sup>(2)</sup> Loss per share is based on the consolidated net loss for the period divided by the weighted average number of shares outstanding during the period, which includes those held in escrow. Diluted loss per share is computed in accordance with the treasury stock method and based on the weighted average number of shares and dilutive share equivalents.

The words "we", "our", "us", "Company", and "Convalo" refer to Convalo Health International Corp and/or the management and employees of the Company.

## ABOUT OUR BUSINESS

### **Convalo Business Summary**

Convalo is a public Canadian company<sup>(1)</sup> focused on the United States outpatient rehabilitation market through its wholly-owned subsidiary, BLVD Centers, Inc. ("BLVD"), which serves clients with addictive and co-occurring disorders. The BLVD philosophy emphasizes mindfulness, meditation, trauma work, giving back, creative self-expression and community, all to achieve a deeply soulful and sustainable recovery. In conjunction with the 12-Step approach, BLVD also offers additional insurance-reimbursed services catered to a variety of communities: gender specific, creatively-oriented, meditation/mindfulness and LGBT affirmative. BLVD offers access to a wide range of services helpful to the recovery process of clients.

Convalo is focused on the business operations of BLVD. Specifically, it is dedicated to the treatment of insurance-reimbursed and private pay clients in the United States, who suffer from alcohol abuse, drug abuse, process addiction and other addictions. The employees of BLVD work with each individual client to develop a schedule that promotes their recovery, which may include group therapy, case management, individual therapy, wellness and life skills mentoring, 12-Step integration, staff support, random drug and alcohol screenings, and five-star amenities.

BLVD offers programs designed as either:

- (a) the second phase in a long-term comprehensive program; or
- (b) community fellowship and extra-support for individuals in need.

*(1) Convalo, which was a private company, became public on February 11, 2015 through a qualifying transaction with Valiant Minerals Ltd.*

### **Amalgamation and private placement**

On February 11, 2015 Convalo and Valiant Minerals Ltd. ("Valiant"), a corporation incorporated under the BCBCA and listed on the NEX trading board of the TSX Venture Exchange (the "Exchange"), completed a triangular amalgamation (the "Amalgamation"), whereby Valiant amalgamated with a wholly owned subsidiary of Convalo, 0986282 B.C. Ltd. (the "Amalgamation Entity"), to form an amalgamated corporation (named Convalo Health Corp.). As a result of the Amalgamation all of the property and assets of Valiant and the Amalgamation Entity became the property and assets of Convalo Health Corp., and all of the liabilities and obligations of Valiant and the Amalgamation Entity became liabilities of Convalo Health Corp. Following the Amalgamation Convalo obtained the listing status of Valiant and Valiant ceased to be a reporting issuer on the Exchange. Convalo trades under the trading symbol "CXV".

The Amalgamation provided for the issuance of 5,900,000 Convalo shares to the Valiant shareholders being one Convalo share issued in exchange for every two Valiant shares issued and outstanding. Convalo Health Corp. issued to Convalo one fully paid issued and outstanding share in the capital of the Convalo Health Corp. in exchange for each one Convalo Sub share held and subsequently Convalo Health Corp. became a wholly owned subsidiary of Convalo.

In conjunction with the Amalgamation, Valiant completed a non-brokered private placement of 58,140,000 subscription receipts for gross proceeds of \$2,907,000. Each subscription receipt entitled the holder, prior to the Amalgamation, to acquire one share in the capital of Valiant and one warrant. These subscription receipts were automatically exchanged for 29,070,000 Convalo shares and warrants exercisable for 29,070,000 Convalo shares. Broker warrants issued in connection with the private placement were automatically exchanged for warrants exercisable for 1,989,400 Convalo shares.

### **Key Performance Drivers**

Our outpatient service revenue line is based on enrollment of clients that suffer from addiction requiring them to get outpatient care for recovery.

BLVD is located in Los Angeles, California and is responsible for supporting the clients that enroll in recovery programs. This facility's operational efficiency is a key to achieving industry-leading client success rates, and maintaining insurance reimbursement. BLVD is committed to compliance with all applicable regulations, the delivery of quality service, and ensuring the highest level of care for our clients.

The growing market of outpatient services provides significant opportunity to garner market share and the Company's operational efficiency is a key to driving more client business to BLVD, thus increasing revenues and gross profits.

### **Future Outlook**

**Expansion through acquisitions of new markets:** A major focus for 2015 is on several types of opportunities to grow and

ABOUT OUR BUSINESS (continued)

**Future Outlook (continued)**

expand service lines with large client bases that have the ability to expand enrollment of clients who fit our existing lines of business. As we continue to grow and achieve scale, the anticipated increase in cash generated from operations can be used to market our service and to gain additional market share. We will continue to pursue acquisitions of other types of clinics to expand our operations.

**Organic Growth:** A top priority continues to be organic growth, the generation of net profit, positive cash flow, and positive EBITDA. Our niche approach utilizes an alternative to the 12-step program and our other client focused initiatives provide high-touch client care. As we continue to expand services in our existing markets, we will leverage our core competencies and existing business platform to enter into new markets.

Going forward, we seek to find ways to continue to grow our client base and penetrate the market to streamline our operational platform and generate positive cash flow and operational profits. We will continue to improve on operational efficiencies and management as they are key execution points in order to achieve healthy gross margins while growing revenues via the cross selling of services to existing and new clients.

OPERATING RESULTS

**Accounting Policies and Estimates**

The consolidated financial statements for the three months ended February 28, 2015 and February 28, 2014 are reported under International Financial Reporting Standards ("IFRS") issued by the governing body of the International Accounting Standards Board ("IASB"). The preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities, and the reported amounts of revenues and expenses for the period of consolidated financial statements.

**Non-IFRS Measures**

Throughout this MD&A, references are made to a number of measures which are believed to be meaningful in the assessment of the Company's performance. All of these metrics are non-standard measures under IFRS, and may not be identical to similarly titled measures reported by other companies. Also, in the future, we may disclose different non-IFRS financial measures in order to help our investors more meaningfully evaluate and compare our future results of operations to our previously reported results of operations. Readers are cautioned that the disclosure of these items is meant to add to, and not replace, the discussion of financial results as determined in accordance with IFRS. The primary purpose of these non-IFRS measures is to provide supplemental information that may prove useful to investors who wish to consider the impact of certain non-cash or uncontrollable items on the Company's operating performance and who wish to separate revenues and related costs associated with client acquisition that may not be ongoing.

**Adjusted EBITDA**

In calculating Adjusted EBITDA certain items are excluded from net loss including interest, taxes, amortization and non-cash share-based payments. Set forth below are descriptions of the financial items that have been excluded from net loss to calculate Adjusted EBITDA and the material limitations associated with using this non-IFRS financial measure as compared to net loss.

- Depreciation and amortization expense may be useful for investors to consider because they generally represent the wear and tear on our property and equipment used in our operations. However, we do not believe these charges necessarily reflect the current and ongoing cash charges related to our operating costs.
- The amount of interest expense we incur or interest income we generate may be useful for investors to consider and may result in current cash inflows or outflows. However, we do not consider the amount of interest expense or interest income to be a representative component of the day-to-day operating performance of our business.
- Income tax expense may be useful for investors to consider because it generally represents the taxes which may be payable for the period and the change in deferred income taxes and may reduce the amount of funds otherwise available for use. However, we do not consider the amount of income tax expense to be a representative component of the day-to-day operating performance of our business.
- Stock based compensation may be useful for investors to consider because it is an estimate of the non-cash component of compensation received by the Company's directors, officers, employees, vendors and consultants for services rendered. However, stock-based compensation is being excluded from the Company's operating expenses because the decisions which gave rise to these expenses were not made to increase revenue in a

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

**OPERATING RESULTS (CONTINUED)**

**Non-IFRS Measures (continued)**

Adjusted EBITDA (continued)

particular period, but were made for the Company's long-term benefit over multiple periods. While strategic decisions, such as those to issue share-based payments are made to further the Company's long-term strategic objectives and do impact the Company's earnings under IFRS, these items affect multiple periods and management is not able to change or affect these items within any particular period.

- Stock exchange listing fee may be useful for investors to consider as this is a non-cash, non-recurring expense associated with the Amalgamation transaction, which the Company executed in order to achieve listing status on the Exchange.

Adjusted EBITDA Before Business Development Costs

Business Development costs may be useful for investors to consider because they represent the costs incurred during the period to acquire new clients and get them enrolled in our service. However, we view Business Development Costs as investments that enable expansion and growth but do not necessarily consider them a representative component of the day-to-day operating performance of our business.

Management uses both IFRS and non-IFRS measures when planning, monitoring, and evaluating the company's performance.

Management uses both IFRS and non-IFRS measures when planning, monitoring, and evaluating the company's performance.

The following table shows our Non-IFRS measures reconciled to our net loss for the indicated periods:

	Three Months Ended February 28, 2015	Three Months Ended February 28, 2014
<b>Net loss</b>	<b>\$ (163,282)</b>	<b>\$ (28,288)</b>
Add back:		
Depreciation and amortization	2,998	33
Interest expense/(interest income)	(706)	-
Provision for income taxes	-	-
Stock based compensation	21,111	-
Transaction costs	317,238	-
<b>Adjusted EBITDA</b>	<b>\$ 177,359</b>	<b>\$ (28,255)</b>
Add back:		
New facility start-up costs	68,318	-
<b>Adjusted EBITDA before new facility start-up costs</b>	<b>\$ 245,677</b>	<b>\$ (28,255)</b>

**Consolidated Operating Results**

Consolidated Statement of Operations and Deficit	Three Months Ended February 28, 2015	Three Months Ended February 28, 2014
<b>Revenue</b>	<b>\$ 1,201,225</b>	<b>\$ -</b>
<b>Expenses</b>	<b>1,364,507</b>	<b>28,288</b>
<b>Net loss</b>	<b>\$ (163,282)</b>	<b>\$ (28,288)</b>
Deficit, beginning of period	(1,943,096)	-
<b>Deficit, end of period</b>	<b>\$ (2,106,378)</b>	<b>\$ (28,288)</b>

**Consolidated Statement of Other Comprehensive Loss**

<b>Net loss</b>	<b>\$ (163,282)</b>	<b>\$ (28,288)</b>
Cumulative translation adjustment	128,830	42,044
<b>Comprehensive (loss)/gain</b>	<b>\$ (34,452)</b>	<b>\$ 13,756</b>
Basic and diluted loss per share	\$ (0.002)	\$ (0.001)

OPERATING RESULTS (CONTINUED)

**Non-IFRS Measures (continued)**

Adjusted EBITDA Before Business Development Costs (continued)

Revenue

For the three months ended February 28, 2015 and 2014, revenues totaled \$1,201,225 and \$nil, respectively.

Cost of revenues and gross margin

For the three months ended February 28, 2015 and 2014, cost of revenues were \$405,198 and \$nil, respectively.

For the three months ended February 28, 2015 and 2014, gross margin was 66.3% and nil%, respectively.

Cost of revenues is comprised primarily of wages paid to the Clinical Director, Clinicians, and Group Facilitators, along with Commissions, Program Supplies, Testing Supplies and Bed Vouchers. These expenses are directly correlated to changes in revenue and we expect the cost of revenues percentage, as it pertains to revenue, will remain consistent over the next year.

Sales and marketing

For the three months ended February 28, 2015 and 2014, sales and marketing expenses totaled \$161,568 and \$nil, respectively. Sales and marketing costs are comprised primarily of salaries, commissions and related expenses for sales personal and other expenses incurred to acquire new clients and get them enrolled in our service, salaries and related expenses for marketing personal, and costs related to advertising. Sales and marketing expenses are directly correlated to changes in revenues and accordingly we expect the cost of sales and marketing as a percentage of revenues to remain consistent over the next year.

General and Administrative

For the three months ended February 28, 2015 and 2014, general and administrative expenses totaled \$149,035 and \$28,288 respectively. General and administrative expenses are comprised primarily of salaries and related expenses for finance, accounting, management, and human resource personnel, along with bad debt expenses, professional services and general overhead. While we expect certain general and administrative expenses that are directly correlated with revenue to increase, we do not expect most general and administrative expenses to increase significantly over the next year, other than as a result of opening new client facilities or offices.

New facility start-up costs

For the three months ended February 28, 2015 and 2014 new facility start-up costs totaled \$68,318 and \$nil, respectively. New facility start-up costs represent non-capitalizable costs incurred to set up a new operating facility and are generally incurred prior to any revenue being generated by the new facility. We expect to continue to incur new facility start-up costs as the Company expands the number of locations it operates, however as a percentage of revenues these costs should fall over time.

Stock based compensation

Subsequent to the Amalgamation transaction, the Company implemented an incentive stock option plan that provides that the board of directors of Convalo may from time to time, in its discretion and in accordance with Exchange requirements, grant to directors, officers and employees and consultants of Convalo, non-transferable options to purchase Convalo shares, provided that the number of Convalo shares reserved for issuance will not exceed 10% of the total issued and outstanding Convalo shares, exercisable for a period of up to ten (10) years from the date of the grant. The number of Convalo shares reserved for issuance to any individual director or officer of Convalo will not exceed 5% of the issued and outstanding Convalo shares and the total number of options awarded to any one consultant in any twelve month period shall not exceed 2% of the issued and outstanding shares of Valiant at the date that the particular option was granted without consent being obtained from the Exchange. The exercise price of any options granted under the Convalo option plan shall not be less than the closing price of Convalo shares on the day preceding the day on which the directors grant such options, less any discount permitted by the Exchange. Options held by a director or employee who ceases to be employed by Convalo expire one year from the date the director or ceases to be a director of Convalo or the employee ceases to be employed by Convalo.

Pursuant to this plan, on February 11, 2015, the Company issued a total of \$8,165,000 options to directors, employees and consultants at a weighted average exercise price of \$0.11. These options vest over a three year period and have five to ten year lives.

---

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

---

**OPERATING RESULTS (CONTINUED)****Non-IFRS Measures (continued)****Stock based compensation (continued)**

For the three months ended February 28, 2015 and 2014 stock based compensation was \$21,111 and \$nil, respectively. Stock based compensation represents the amortization of the fair value of options and warrants issued to the Company's directors, officers, employees, vendors and consultants for services rendered. We expect stock based compensation to increase in the second quarter reflecting a full quarter of amortization of stock options issued in February 2015. Although we expect to issue additional warrants and options in the future, as the Company's revenues increase overall stock compensation is expected to decline as a percentage of revenue.

**Transaction costs**

As a result of the Amalgamation, the Company issued 5,900,000 shares of common stock valued at \$590,000. In return the Company obtained \$304,270 of cash from Valiant and assumed \$31,658 of payables. The difference between the fair value of the shares issued and the net assets acquired of \$317,388 has been attributed to the cost of obtaining Valiant's listing status. This was a one-time cost and is not expected to recur.

**Net Loss**

For the three months ended February 28, 2015 and 2014, the Company incurred a net loss of \$163,282 and \$28,288, respectively. The Company expects its losses to narrow as revenues continue to grow and it maintains a strong gross margin.

**Comprehensive Loss**

For the periods ended February 28, 2015 and 2014, the Company incurred a comprehensive loss of \$34,452 and a comprehensive gain of \$13,756, respectively.

The difference between net loss and comprehensive loss for the respective periods relate to foreign currency translation adjustment which records exchange differences arising on translation of foreign controlled subsidiaries and loans between the members of the group.

**FINANCIAL CONDITION**

	February 28, 2015	November 30, 2014
Cash	\$ 5,402,596	\$ 1,840,298
Accounts receivable	903,355	326,332
Prepaid expenses	43,427	8,929
Loans receivable	-	15,975
Deferred share issuance costs	-	151,280
Property and equipment	72,180	53,318
Restricted cash	-	277,040
Deposits	421,292	402,010
<b>Total assets</b>	<b>\$ 6,842,850</b>	<b>\$ 3,075,182</b>
Accounts payable and other current liabilities	741,907	749,469
<b>Total liabilities</b>	<b>\$ 741,907</b>	<b>\$ 749,469</b>
Share capital and contributed surplus	7,967,025	4,157,343
Deficit	(2,106,378)	(1,943,096)
Accumulated other comprehensive gain (loss)	240,296	111,466
<b>Shareholders' equity</b>	<b>\$ 6,100,943</b>	<b>\$ 2,325,713</b>

**Liquidity**

As at February 28, 2015, the Company had cash on hand of \$5,402,596. Management considers liquid assets to consist of cash and cash equivalents, accounts receivable, inventory, prepaid expenses and other current assets. According to this definition, the company's liquid assets equal the current assets totaling \$6,349,378. While working capital is traditionally used as a measure of a company's liquidity, management believes that a more accurate view of the Company's liquidity is liquid assets less current liabilities. The Company's liquid assets less current liabilities equal \$5,607,471.

**FINANCIAL CONDITION (continued)****Capital Resources**

As of February 28, 2015, additional financing may be required in the future to fund operations until the Company is profitable, if ever. There is no assurance that such funding will be available or obtained on favorable terms. The Company's consolidated financial statements do not include the adjustments that would be necessary should the Company be unable to continue as a going concern.

**Capital Management**

The Company considers its capital to be shareholders' equity, which is comprised of share capital, contributed surplus, accumulated other comprehensive income and deficit, which totaled \$6,100,943 at February 28, 2015.

The Company plans to raise capital, as necessary, to meet its needs and take advantage of perceived opportunities and, therefore, does not have a numeric target for its capital structure. Funds are primarily secured through equity capital raised by way of private placements and convertible notes. There can be no assurance that the Company will be able to continue raising capital in this manner.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

The Company invests all capital that is surplus to its immediate operational needs in short-term, liquid and highly rated financial instruments, such as cash and short-term guarantee deposits, held with major Canadian and US financial institutions.

**Financing**

The Company has financed its operations primarily from equity financings. During the quarter ended February 2015, the Company issued 5,900,000 shares to Valiant shareholders in connection with the Amalgamation transaction described above. The Amalgamation has been accounted for as a purchase of the assets and liabilities of Valiant and not a business combination. As a result the Company acquired \$304,270 in cash that Valiant had on hand.

In conjunction with the Amalgamation, Valiant completed a non-brokered private placement of 58,140,000 subscription receipts at a price of \$0.05 per subscription receipt for aggregate gross proceeds of \$2,907,000. Each subscription receipt issued in connection with the private placement entitled the holder, just prior to the Amalgamation, to acquire one common share in the capital of Valiant and (i) one-half of one transferable share purchase warrant (a "Valiant A Warrant"), with each whole Valiant A Warrant entitling the holder to acquire one Valiant Share at a price of \$0.10 per share until the date that is the earlier of (a) thirty (30) months from the date of issuance, and (b) ninety (90) days following the Amalgamation, and (ii) one-half of one transferable share purchase warrant (a "Valiant B Warrant"), with each whole Valiant B Warrant entitling the holder thereof to acquire one Valiant Share at a price of \$0.10 per share until the date that is the earlier of (a) thirty (30) months from the date of issuance, and (b) twelve (12) months following the Amalgamation. In connection with the private placement 3,978,800 broker warrants were issued at an exercise price of \$0.05 per Valiant share exercisable for a period of 24 months. Pursuant to the Amalgamation each Valiant share, A Warrant and B Warrant issued pursuant to a subscription receipt, and each broker warrant issued pursuant to the private placement was exchanged for similar securities of Convalo on a one for two basis, and with the exercise price of the warrants increased by 100%. As a result, immediately following the Amalgamation, Convalo issued 29,070,000 shares at \$0.10 per share, 29,070,000 warrants exercisable at \$0.10 per share and 1,989,400 broker warrants exercisable at \$0.10 per share. The warrants issued were valued at \$318,760 and the broker warrants were valued at \$104,490. Costs directly attributable to the private placement amounted to \$198,890.

During the first quarter of 2015 a total of 2,402,500 warrants and 350,000 broker warrants were exercised at a weighted average exercise price of \$0.1873 per share for total proceeds of \$515,500.

Including the above, as of February 28, 2015, the Company has raised approximately \$7,900,000 from the sale and issuance of equity securities. The Company will continue to rely on equity financings and, potentially, debt or quasi-debt securities to fund the business for its first few years of operations.

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FINANCIAL CONDITION (continued)

#### Subsequent Events

Subsequent to February 2015, an additional 23.2 million warrants and broker warrants, which were outstanding at February 28, 2015, have been exercised at a weighted average exercise price of \$0.193 for total gross proceeds of \$4.5 million.

On April 22, 2015 (the "Closing"), the Company closed on a bought deal private placement of 43,125,000 units. Each Unit consists of one common share in the capital of Convalo issued at \$0.40 per common share, and one warrant of Convalo. Each Warrant entitles the holder thereof to acquire one common share for an exercise price of \$0.50 per common share for a period of 36 months following the closing of the offering. The expiry date of the Warrants may be accelerated by Convalo at any time following the six-month anniversary of the Closing and prior to the expiry date of the Warrants if the volume-weighted average trading price of the Company's common shares is greater than \$0.60 for any 20 consecutive trading days. The Company received gross proceeds of \$17,250,000 and incurred cash share issuance costs of \$862,500. In addition, the Company issued 2,156,250 broker warrants to the underwriters.

#### Commitments

##### Operating Leases

The Company leases certain facilities under the terms of non-cancelable operating leases. For the three month periods ended February 28, 2015 and 2014, amounts included in facilities expense totaled \$122,086 and \$nil, respectively. Future payments in US dollars pursuant to these commitments are as follows:

Three month period ending February 28, 2015		US \$
Less than 1 year	\$	501,029
Between 1 and 5 years		1,650,697
<b>Total</b>	<b>\$</b>	<b>2,151,726</b>

##### Related Party Transactions

On October 1, 2013, the Company entered into an agreement with Canons Park Advisors, Inc. ("Advisor"), an entity that is wholly owned by directors of the Company<sup>1</sup>, in which the Advisor will act as a financial and management advisor to the Company. Pursuant to the terms of the agreement, the Advisor is entitled to a variety of payments based on certain milestones. As of February 28, 2015, \$57,032 has been accrued related to this agreement (of which, \$30,000 was incurred in Fiscal Year 2013) and these amounts are included in the disclosure of compensation of key management personnel.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including executive directors. The total compensation of key management personnel is as follows:

	Three Months Ended February 28, 2015	Three Months Ended February 28, 2014
Salaries and short term benefits	\$ 30,000	\$ 30,000
Share based payments	8,062	-
	<b>\$ 38,062</b>	<b>\$ 30,000</b>

<sup>1</sup> Canons Park Advisors, Inc. is wholly owned by Michael Dalsin and Roger Greene.

#### Off Balance Sheet Arrangements

The Company has no material undisclosed off-balance sheet arrangements that have or are reasonably likely to have, a current or future effect on its results of operations or financial condition.

## ACCOUNTING AND DISCLOSURE MATTERS

#### Financial Reporting Controls

Management has established disclosure controls and procedures for the Company in order to provide reasonable assurance that material information relating to the Company is made known to it in a timely manner. Management has evaluated the

**Financial Reporting Controls (continued)**

effectiveness of the Company's disclosure controls and procedures, as of the date of this report, and is not aware of any material changes to these controls and procedures; it believes them to be effective in providing such reasonable assurance.

Management is also responsible for the design of internal controls over financial reporting in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with IFRS. Management has evaluated the design of the Company's internal controls and procedures over financial reporting as of the end of the period covered by the annual filings, and believes the design to be sufficient to provide such reasonable assurance.

While management believes that the current disclosure and internal controls and procedures provide a reasonable level of assurance, it cannot be expected that existing disclosure controls and procedures or internal financial controls will prevent all human error and circumvention or overriding of controls and procedures. A control system, no matter how well conceived or operated can only provide reasonable, not absolute, assurance that the objectives of the control system are met.

**Critical Accounting Estimates**

The preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the consolidated financial statements. We constantly evaluate these estimates and assumptions.

We base our estimates and assumptions on past experience and other factors that are deemed reasonable under the circumstances. This involves varying degrees of judgment and uncertainty, thus the amounts currently reported in the consolidated financial statements could prove to be inaccurate in the future.

We consider the estimates and assumptions described in this section to be an important part in understanding the consolidated financial statements. These estimates and assumptions are subject to change, as they rely heavily on management's judgment and are based on factors that are inherently uncertain.

**Revenue Recognition**

Revenue is recognized when it is probable that the economic benefits associated with a transaction will flow to the Company, and when the amount of revenue can be reliably measured. If these amounts are not known at the time the service is rendered, management will make an estimate as to the amount. Client service revenues are recognized as the related services are provided. Interest revenues are recognized using the effective interest method.

**Stock-Based Compensation**

The Company accounts for stock-based compensation, including stock options and warrants, using the fair value method as prescribed by IFRS 2. Under this method, the fair value of stock options and warrants at the date of grant is amortized to stock compensation expense over the vesting period and the offsetting credit is recorded as an increase in contributed surplus. The Company accounts for forfeitures as they happen.

For the three month period ended February 28, 2015, the Company recorded stock-based compensation expense of \$21,111 (2014 - \$nil).

For the three months ended February 28, 2015, the fair value of the vested stock options was determined using the Black-Scholes option pricing model with the following assumptions :

Expected option life	5 – 10 years
Expected volatility	100%
Risk-free interest rate	1%
Dividend yield	Nil
Weighted average share price at grant date	\$0.11
Weighted average exercise price	\$0.11

---

**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**ACCOUNTING AND DISCLOSURE MATTERS (CONTINUED)**

---

Accounts Receivable

Accounts receivable are recorded at the time revenue is recognized, net of contractual allowances and are presented on the balance sheet net of allowance for doubtful accounts. The Company performs analyses to evaluate the net realizable value of accounts receivable as of the balance sheet date. Specifically, the Company considers historical realization data, accounts receivable aging trends, other operating trends and relevant business conditions. Because of continuing changes in the health care industry and third party reimbursement, it is possible that our estimates could change, which could have a material impact on our operations and cash flows.

**FINANCIAL INSTRUMENTS AND RISK MANAGEMENT**

**Financial instrument risk exposure**

The Company's activities expose it to a variety of financial risks: market risk (including price risk, currency risk and interest rate risk), credit risk and liquidity risk. These risks arise from the normal course of operations and all transactions are undertaken to support the Company's ability to continue as a going concern. The Company's financial risk management goals are to ensure that the outcome of activities involving elements of risk are consistent with the Company's objectives and risk tolerance, while maintaining an appropriate risk/reward balance and protecting the Company's consolidated balance sheet from events that have the potential to materially impair its financial strength. Balancing risk and reward is achieved through identifying risk appropriately, aligning risk with overall business strategy, diversifying risk, pricing appropriately for risk, mitigation through preventative controls, and transferring risk to third parties.

Market risk

*Foreign Currency Risk*

A significant portion of the Company's revenues are transacted in U.S. dollars and as a result, fluctuations in the rate of exchange between the U.S. dollar and Canadian dollar can have a significant impact on the Company's cash flows and reported results. As a majority of the Company's operating expenses are also in United States dollars, operational foreign currency risk is limited.

At February 28, 2015, the consolidated statement of financial position includes \$1,643,743 of cash, \$903,355 of accounts receivable, and \$388,054 of accounts payable and accrued liabilities denominated in U.S. dollars. At November 30, 2014, the Company had cash of \$1,604,306, \$285,980 of accounts receivable, and \$214,255 of accounts payable and accrued liabilities denominated in U.S. dollars.

The Company's revenues and expenses denominated in U.S. dollars for the period ended November 30, 2014 were USD \$999,854 and USD \$854,764 respectively. Accordingly, a 10 percent increase or decrease in the value of the U.S. dollar relative to its Canadian counterpart would result in a \$14,509 increase or decrease in net loss.

The functional currency for all of the Company's foreign operations is the US dollar which is the local currency. The Company translates the assets and liabilities of its US dollar functional currency subsidiaries into Canadian dollars using exchange rates in effect at the end of each period. Revenue and expenses for these subsidiaries are translated using average exchange rates that approximate those in effect during the period. The Company is affected by the fluctuations in the value of the US dollar. Significant fluctuations of exchange rates could adversely affect the Company's financial condition and results of operations. At the present, the Company maintains cash balances in both US and Canadian dollars, but does not purchase any securities or financial instruments to speculate on or hedge against a rise or fall in the value of the US Dollar.

Credit Risk

Credit risk is the potential that clients or a counterparty to a financial instrument fail to meet their obligation to the Company. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily to trade accounts receivable as the Company's revenues are concentrated to California. The Company had many customers during the course of the year and believes that there is minimal risk associated with collection of these amounts. The Company manages its credit risk by evaluating the eligibility of its clients for insurance or other coverage prior to admittance.

All of the Company's accounts receivable are neither past due nor impaired as it awaits formal recognition from insurers as a pre-approved service. Credit risk is generally limited to the risk that the estimated amount of revenue that can be collected is not accurate.

There were no provisions for doubtful accounts recorded during the period as amounts collected were not less than the amounts initially recognized as revenue.

---

**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONTINUED)**

---

Liquidity Risk

Liquidity risk is the risk the Company will encounter difficulties in meeting its financial liability obligations as they become due. The Company manages its liquidity risk through cash management. In managing liquidity risk, the Company maintains access to equity markets, the availability of which is dependent on market conditions. The Company monitors its requirements through the use of rolling future net cash flow projections and budgets and believes it has sufficient funding through its current cash position to continue operating for the foreseeable future. All future liabilities are current and due within the next twelve months.

**RISK FACTORS**

***Due to the nature of Convalo's business, the legal and economic climate in which Convalo operates and the present stage of development of its business, Convalo may be subject to significant risks. Convalo's future development and actual operating results may be very different from those expected as at the date of this MD&A. There can be no certainty that Convalo will be able to implement successfully the strategy set out herein. No representation is or can be made as to the future performance of Convalo and there can be no assurance that Convalo will achieve its objectives. In addition to the other information in this MD&A, an investor should carefully consider each of, and the cumulative effect of, the following factors.***

An investment in Convalo's shares should be considered highly speculative due to the nature of Convalo's business and the present stage of its development. In evaluating Convalo and its business, shareholders should carefully consider the following risk factors. These risk factors are not a definitive list of all risk factors associated with Convalo or in connection with their operations. It is believed that these are the factors that could cause actual results to be different from expected and historical results. You should not rely upon forward-looking statements as a prediction of future results. Additional risks and uncertainties that Convalo is unaware of, or that Convalo currently deems to be immaterial, may also become important factors that affect Convalo. If any of the risks actually occur, the business, financial condition or results of operations could be materially adversely affected, with the result that the trading price of Convalo or Convalo's shares, as applicable, could decline and the shareholder could lose all or part of his or her investment.

***Ability to Manage Growth***

Recent rapid growth in all areas of Convalo's business has placed, and is expected to continue to place, a significant strain on its managerial, operational and technical resources. Convalo expects operating expenses and staffing levels to increase in the future. To manage such growth, Convalo must expand its operational and technical capabilities and manage its employee base while effectively administering multiple relationships with various third parties. There can be no assurance that Convalo will be able to manage its expanding operations effectively. Any failure to implement cohesive management and operating systems, to add resources on a cost-effective basis or to properly manage Convalo's expansion could have a material adverse effect on its business and results of operations.

***Capital Investment***

The timing and amount of capital expenditures by Convalo will be dependent upon Convalo's ability to utilize credit facilities, raise new debt, generate cash from operations, meet working capital requirements and sell additional shares in order to accommodate these items. There can be no assurance that sufficient capital will be available on acceptable terms to Convalo for necessary or desirable capital expenditures or that the amount required will be the same as currently estimated. Lack of these funds could limit the future growth of Convalo and its subsidiaries and their respective cash flows.

***Competition***

Convalo will participate in a highly competitive market, which may become more competitive as new players enter. Certain competitors will be subsidiaries or divisions of larger, much better capitalized companies. Certain competitors will have vertically integrated services sectors of the market. Convalo will have less capital and may encounter greater operational challenges in serving the market.

***Dependence upon Management***

Although Convalo is expected to have experienced senior management and personnel, Convalo will be substantially dependent upon the services of a few key personnel, particularly Michael Dalsin and Roger Greene, for the successful operation of its business. The loss of the services of any of these personnel could have a material adverse effect on the business of Convalo. Convalo may not be able to attract and retain personnel on acceptable terms given the intense competition for such personnel among competitors. If it loses any of these persons, or is unable to attract and retain qualified personnel, its business, financial condition and results of operations may be materially and adversely affected.

RISK FACTORS (CONTINUED)

***Inability to Implement the Business Strategy***

The growth and expansion of Convalo's business is heavily dependent upon the successful implementation of Convalo's business strategy. There can be no assurance that Convalo will be successful in the implementation of its business strategy.

***Issuance of Debt***

From time to time, Convalo may enter into transactions to acquire assets or the shares of other corporations. These transactions may be financed partially or wholly with debt, which may increase Convalo's debt levels above industry standards. The level of Convalo's indebtedness from time to time could impair Convalo's ability to obtain additional financing in the future on a timely basis to take advantage of business opportunities that may arise.

***Conflicts of Interest***

Certain of the directors of Convalo are also directors and officers of other companies, some of which may be in the healthcare sector, and conflicts of interest may arise between their duties as directors of Convalo and as officers and directors of such other companies. Such conflicts must be disclosed in accordance with, and are subject to such other procedures and remedies as apply under the applicable corporate statute.

***Dilution and Future Issuances of Convalo Shares***

Convalo may issue additional shares in the future, which may dilute a shareholder's holdings in Convalo.

***Future Sales of Convalo Shares by Directors and Officers***

Subject to compliance with applicable securities laws, directors and officers and their affiliates may sell some or all of their securities in Convalo in the future. No prediction can be made as to the effect, if any, such future sales will have on the market price of Convalo's securities prevailing from time to time. However, the future sale of a substantial number of securities by Convalo's directors and officers and their controlled entities, or the perception that such sales could occur, could adversely affect prevailing market prices for Convalo's securities.

***Reimbursement Rates May Decline***

Reimbursement for services to be provided by Convalo will come primarily from Medicare, the *Patient Protection and Affordable Care Act* ("PPACA") and private health insurance companies. The reimbursement rates offered are outside the control of Convalo. Reimbursement rates in the United States, and much of the United States healthcare market in general, have been subject to continual reductions as health insurers and governmental entities attempt to control healthcare costs. The extent and timing of any reduction in reimbursement rates cannot be predicted by Convalo.

Reductions in reimbursement rates can have a material impact on the profitability of Convalo's operations. A reduction in reimbursement may be unrelated to any concurrent decline in the cost of operations, thereby resulting in reduced profitability. Convalo's costs of operations could increase, but the cost increases may not be passed on to customers because reimbursement rates are set without regard to the cost of service.

***Requirement for Permits and Licences in a Highly Regulated Business***

Some operations of Convalo require certain licences and permits from the authorities in the United States. The ability of Convalo to obtain, sustain or renew any such licences and permits on acceptable terms is subject to changes in regulations and policies and to the discretion of the applicable authorities or other governmental agencies. There is no guarantee that Convalo will be able to obtain such licences and permits.

Convalo will be subject to regulation from both United States federal and state authorities. Regulatory action could disrupt Convalo's ability to provide services. Such regulatory action could come in the form of actions based upon Convalo's operation. Regulatory action could prevent or delay reimbursement for certain services. There could also be legislative action that could adversely affect Convalo's business model, including a decision by the United States government to become the exclusive provider of healthcare services at some time in the future. Conversely, budgetary problems in the United States could lead to reduced funding, substantial modification or elimination of Medicare programs, which would end reimbursement for many patients. There can be no assurance that new rules and regulations will not be enacted or that existing rules and regulations will not be applied in a manner which could limit or curtail the business of Convalo. Amendments to current laws and regulations could have a substantial adverse impact on Convalo.

**RISK FACTORS (CONTINUED)*****Privacy Legislation***

The *Health Insurance Portability and Accountability Act of 1996* ("HIPAA") required the United States Department of Health and Human Services to adopt standards to protect the privacy and security of individually identifiable health-related information. The department released regulations containing privacy standards in December 2000 and published revisions to the final regulations in August 2002. The privacy regulations extensively regulate the use and disclosure of individually identifiable health related information. The regulations also provide patients with significant new rights related to the understanding and controlling how their health information is used or disclosed. The security regulations require healthcare providers to implement administrative, physical and technical practices to protect the security of identifiable health information that is maintained or transmitted electronically.

In addition to HIPAA, there are numerous federal and state laws and regulations addressing patient and consumer privacy concerns, including unauthorized access or theft of personal information. State statutes and regulations vary from state to state. Lawsuits, including class actions and action by state attorneys general, directed at companies that have experienced a privacy or security breach can also occur.

***Privacy Legislation (continued)***

Convalo believes that the cost of compliance with HIPAA and other federal and state privacy laws will not have a material adverse effect on its business, financial condition, results of operations or cash flows. However, there can be no assurance that a breach of privacy or security will not occur. If there is a breach, Convalo may be subject to various penalties and damages and may be required to incur costs to mitigate the impact of the breach on affected individuals.

***ICD-10 Coding System***

Within the United States, health insurance plans and health care providers are required to transition to a new version of the standardized procedure coding system, ICD-10. This new version significantly expands the number and detail of billing codes used for third-party claims. Use of the ICD-10 system may be required beginning October 1, 2015. Transition to the new ICD-10 system requires significant investment in coding technology and software as well as the training of staff involved in the coding and billing process. In addition to these upfront costs of transition to ICD- 10, it is possible that Convalo could experience disruption or delays in payment due to technical or coding errors or other implementation issues involving Convalo's systems or the systems and implementation efforts of health insurance plans and their business partners.

***Strategic Relationships with Third Parties***

Convalo anticipates that it will continue to depend on the relationships with various third parties, including hospitals, long-term care facilities and physicians to grow its business. Identifying, negotiating and documenting relationships with third parties requires significant time and resources. Convalo's competitors may be effective in providing incentives to their parties to favour their solutions or may prevent Convalo from developing strategic relationships with these parties. In addition, these third parties may not perform as expected under any agreement with them and Convalo may have disagreements or disputes with these parties, which could negatively affect Convalo's brand and reputation. It is possible that these third parties may not be able to devote the resources that Convalo expects from the relationship. If Convalo is unsuccessful in establishing or maintaining its relationship with these third parties, Convalo's ability to compete in the marketplace or to grow its revenue could be impaired, and operating results would suffer. Even if Convalo is successful, these relationships may not result in improved operating results.

***Referrals***

The success of Convalo is primarily dependent upon physician referrals of patients for assessment and rehabilitation procedures. These referrals come through preferred provider and other service agreements established through competitive tendering processes. If Convalo's physician relationships were to decline in number, the business, financial condition and results of operations of Convalo could be adversely affected. Further there is a risk concerning changes in the United States Anti-Kickback Statute and Stark Law and/or similar state laws, rules and regulations.

***Information Technology Systems***

Convalo's business depends, in part, on the continued and uninterrupted performance of its information technology systems. Sustained system failures or interruptions could disrupt Convalo's ability to operate effectively, which in turn could adversely affect its business, results of operations and financial condition. Convalo's computer systems may be vulnerable to damage from a variety of sources, including physical or electronic break-ins, computer viruses and similar disruptive problems. Despite precautions taken and the extensive mitigation strategies put in place by Convalo, unanticipated problems affecting the information technology systems could cause interruptions for which Convalo's insurance policies may not provide adequate compensation.

RISK FACTORS (CONTINUED)

***Insurance and Uninsured Risks***

Convalo's business will be subject to a number of risks and hazards generally, including general liability. Such occurrences could result in damage to facilities, personal injury or death, damage to the properties of Convalo, or the properties of others, monetary losses and possible legal liability.

Although Convalo will maintain insurance to protect against certain risks in such amounts as it considers to be reasonable, its insurance will not cover all potential risks associated with its operations. Convalo may also be unable to maintain insurance to cover these risks at economically feasible premiums. Insurance coverage may not continue to be available or may not be adequate to cover any resulting liability. Convalo might also become subject to liability which may not be insured against or which Convalo may elect not to insure against because of premium costs or other reasons. Losses from these events may cause Convalo to incur significant costs that could have a material adverse effect upon its financial performance and results of operations.

***General Litigation Risk***

Disputes are common in the United States healthcare industry and as such, in the normal course of business, Convalo might be involved in various legal actions and proceedings which arise from time to time, some of which may be substantial. There is no assurance that Convalo's insurance arrangements will be sufficient to cover any particular claim or claims that may arise in the future. Furthermore, Convalo is subject to the risk of claims and legal actions for various commercial and contractual matters in respect of which insurance is not available.

***Exchange Rate Fluctuations***

Exchange rate fluctuations may affect the costs that Convalo incurs in its operations. The appreciation of non-United States dollar currencies against the United States dollar can increase the cost of operations in United States dollar terms.

***Holding Corporation***

Convalo is considered a holding corporation and a substantial portion of its assets is the capital stock of its subsidiaries. As a result, the holders of Convalo shares are subject to risks attributable to its subsidiaries. As a holding corporation, Convalo conducts substantially all of its business through its subsidiaries, which generate substantially all of its revenue. Consequently,

Convalo's cash flows and ability to complete current or desirable future enhancement opportunities are dependent on the earnings of its subsidiaries and the distribution of those earnings to Convalo. The ability of the subsidiaries of Convalo to pay dividends and other distributions depend on their operating results and is subject to applicable laws and regulations which require that solvency and capital standards be maintained by such companies and contractual restrictions contained in ten instruments governing their debt. In the event of bankruptcy, liquidation or reorganization of any of Convalo's subsidiaries, holders of indebtedness and trade creditors will generally be entitled to payment of their claims from the assets of those subsidiaries before any assets are made available for distribution to Convalo.

***Internal Control over Financial Reporting and Disclosure Controls and Procedures***

Convalo may face risks if there are deficiencies in its internal controls over financial reporting and disclosure controls and procedures. Internal controls over financial reporting are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external reporting purposes. Management is responsible for establishing and maintaining adequate internal controls over financial reporting appropriate to the nature and size of Convalo. The board of directors, in conjunction with its Audit Committee, is responsible for assessing the progress and sufficiency of internal controls over financial reporting and disclosure controls and procedures and will make adjustments as necessary. However, these initiatives may not be effective at remedying any deficiencies in internal control over financial reporting and disclosure controls and procedures. Any deficiencies, if uncorrected, could result in Convalo's financial statements being inaccurate and in future adjustments or restatements of its financial statements, which could adversely affect the price of Convalo shares and Convalo's business, financial condition and results of operations.

***Reliance on the Medicare Program***

Convalo will receive payments from a small number of entities, with the Medicare program of the U.S. government being the primary entity making payments. If that entity were to slow payments of Convalo's receivables for any reason, Convalo would be adversely impacted.

***Key Credentialed Employees***

Convalo will rely on a number of key employees and licensed providers with specialized training in the delivery of Convalo's services. Convalo's operations will be adversely affected if any of the key employees cease their employment with Convalo or if Convalo is unable to recruit and retain qualified staff.

RISK FACTORS (CONTINUED)

***Ability to Implement Acquisition Strategy***

Convalo may not be able to effectively implement its acquisition strategy. There is the possibility that Convalo will not be able to reduce costs, improve profits or roll out additional rehabilitation facilities fast enough to meet its objectives.

***Uninsured and Underinsured Clients and Collection Risks***

An increase in uninsured and underinsured clients or the deterioration in the collectability of the accounts of such clients could have a material adverse effect on Convalo's business, financial condition and results of operations. Collection of receivables from third-party payors and clients is critical to Convalo's operating performance. The primary collection risks are (i) the risk of overestimating Convalo's net revenues at the time of billing that may result in Convalo receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that clients will fail to remit insurance payments to Convalo when the commercial insurance company pays out-of-network claims directly to the client, (iv) resource and capacity constraints that may prevent Convalo from handling the volume of billing and collection issues in a timely manner, (v) the risk that clients do not pay Convalo for their self-pay balance (including co-pays, deductibles and any portion of the claim not covered by insurance, and (vi) the risk of non-payment from uninsured clients. Significant changes in business office operations, payor mix or economic conditions, including changes resulting from implementation of the *Affordable Care Act*, could affect Convalo's collection of accounts receivable, cash flows and results of operations.

***Increased State and Federal Investigation of Healthcare Providers***

Both federal and state government agencies have heightened and coordinated their civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and various segments of the healthcare industry. These investigations relate to a wide variety of topics, including relationships with physicians, billing practices and use of controlled substances. The PPACA included an additional \$350 million of federal funding over 10 years to fight healthcare fraud, waste and abuse, including \$40 million for federal fiscal year 2014. From time to time, the Office of Inspector General and the Department of Justice have established national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. In addition, increased government enforcement activities, even if not directed towards our treatment facilities, also increase the risk that Convalo's facilities, physicians and other clinicians furnishing services in Convalo's facilities, or Convalo's executives and directors, could become named as defendants in private litigation such as state or federal false claims act cases or consumer protection cases, or could become the subject of complaints at the various

state and federal agencies that have jurisdiction over Convalo's operations. Any governmental investigations involving any of Convalo's facilities, executives or directors, even if Convalo ultimately prevails, could result in significant expense and could adversely affect Convalo's reputation.

***Uncertainties Regarding the PPACA***

The PPACA provides for increased access to coverage for healthcare and seeks to reduce healthcare-related expenses. Overall, the expansion of health insurance coverage under the PPACA, most of which went into effect on January 1, 2014, is expected to be beneficial to the substance abuse treatment industry. Beginning January 1, 2014, health insurers are prohibited from denying coverage to individuals because of preexisting conditions. Further, all new small group and individual market health plans are required to cover ten essential health benefit categories, which include substance abuse addiction and mental health disorder services. Likewise, as of January 1, 2014, small group and individual market plans are required to comply with the requirements of the MHPAEA of 2008. According to the U.S. Department of Health and Human Services estimates published in February 2013, these changes are expected to expand coverage for substance abuse addiction treatment and mental health disorders treatment for another 62.5 million Americans. The expansion of commercial insurance for substance abuse treatment services under the PPACA may result in a higher demand for services from all providers. This may bring new competitors to the market, some of which may be better capitalized and have greater market penetration than Convalo. Further, Convalo expects increased demand for substance abuse treatment services to also increase the demand for case managers, therapists, medical technicians and others with clinical expertise in substance abuse treatment, which may make it both more difficult to adequately staff Convalo's substance abuse treatment facilities and could significantly increase its costs in delivering treatment, which may adversely affect both its operations and profitability. One of the many impacts of the PPACA has been a dramatic increase in payment reform efforts by federal and state government payors as well as commercial payors. These efforts take many forms including the growth of accountable care organizations, pay-for-performance bonus arrangements, partial capitation arrangements and the bundling of services into a single payment. The end result of these efforts is that more risk of the overall cost of care is being transferred to providers. As institutional providers and their affiliated physicians assume more risk for the cost of care, Convalo expects more services to be furnished within provider networks formed to accept these types of payment reform.

Convalo's ability to compete and retain traditional sources of clients may be adversely affected by Convalo's exclusion from such networks or its inability to be included in such networks. Convalo cannot predict the impact the implementation of the PPACA and related rulemaking and regulations may have on Convalo's business, results of operations, cash flow, capital resources and liquidity or whether Convalo will be able to adapt successfully to the changes required by the PPACA.

RISK FACTORS (CONTINUED)

***Changes to Federal, State and Local Regulations***

Because Convalo's treatment programs and operations are regulated at federal, state and local levels, Convalo could be affected by different regulatory changes in different regional markets. Increases in the costs of regulatory compliance and the risks of noncompliance may increase Convalo's operating costs, and Convalo may not be able to recover these increased costs, which may adversely affect Convalo's results of operations and profitability. Also, because many of the current laws and regulations are relatively new, Convalo does not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. In the future, different interpretations or enforcement of these laws and regulations could subject Convalo's current or past practices to allegations of impropriety or illegality or could require Convalo to make changes to its treatment facilities, equipment, personnel, services or capital expenditure programs. A determination that Convalo has violated these laws, or the public announcement that Convalo is being investigated for possible violations of these laws, could adversely affect Convalo's business, operating results and overall reputation in the marketplace. In addition, federal, state and local regulations may be enacted that impose additional requirements on Convalo's facilities, such as the 2013 changes to the HIPAA privacy and security regulations. Adoption of legislation or the creation of new regulations affecting Convalo's facilities could increase its operating costs, restrain its growth, limit it from taking advantage of opportunities presented and could have a material adverse effect on its business, financial condition and results of operations. Adverse changes in existing comprehensive zoning plans or zoning regulations that impose additional restrictions on the use or requirements with respect to its facilities may affect Convalo's ability to operate its existing facilities or acquire new facilities, which may adversely affect its results of operations and profitability.